Zoryl-M 1 Tablet PR is a combination oral antidiabetic medication containing Glimepiride 1 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production and improving peripheral insulin sensitivity, contributing to reduced blood glucose levels. The extended-release formulation of Zoryl-M 1 Tablet PR allows for sustained drug release, promoting better patient compliance through once-daily dosing and minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination is particularly beneficial for patients inadequately controlled on diet and exercise alone or those requiring dual therapy for optimal glycemic management. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or a history of lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. Zoryl-M 1 Tablet PR should be used under medical supervision, with lifestyle modifications to achieve effective and safe diabetes management.